Isosativan from the Nigerian Propolis Activates the mTORC2/AKT Pathway and Suppresses Muscle Atrophy Genes Atrogin-1 and MuRF1 in Diabetic Rats
Abstract
Objective: The study investigated the effects of Isosativan on the mTORC2/AKT pathway and diabetic muscle atrophy in a rat model of the disease.
Material and Methods: Diabetes was induced by a high-fat diet and administration of a low-dose streptozotocin injection. The animals confirmed to be diabetic were subsequently treated with Isosativan (50 mg/kg) and their responses were evaluated based on muscle atrophy and body weight. Key biochemical pathways were assessed, particularly the mTORC2/AKT signaling pathway and the muscle atrophy genes Atrogin-1 and MuRF1, in order to determine the mechanism underlying the effects of this Isosativan.
Results: Administration of Isosativan resulted in significant improvements in diabetic muscle atrophy. The treated rats exhibited increased levels of the mTORC2 and AKT proteins and maintained relatively higher body weights compared to untreated diabetic controls. The muscle atrophy-related genes, Atrogin-1 and MuRF1, were also significantly suppressed in the treated group.
Conclusion: Isosativan shows promise as a therapeutic agent for combating diabetes and diabetic muscle atrophy, operating through the activation of the mTORC2/AKT pathway, thereby leading to better utilization of glucose. This finding suggests that Isosativan could be a viable treatment option for managing diabetes-related metabolic problems, offering a novel approach for therapeutic intervention in diabetic muscle atrophy.
Keywords
Full Text:
PDFReferences
Shen Y, Hu Y, Wang K, Qi G, Liu H, Wang W, et al. Diabetic muscular atrophy: molecular mechanisms and promising therapies. Front Endo 2022;13.
Espino Gonzalez E, Dalbram E, Mounier R, Gondin J, Farup, J, Jesse N, et al. Impaired skeletal muscle regeneration in diabetes: from cellular and molecular mechanisms to novel treatments. Cell Metab 2024;36:1204-36.
D’Souza M, Al Sajee D, Hawke TJ. Diabetic myopathy: impact of diabetes mellitus on skeletal muscle progenitor cells. Front Physiol 2013;4.
Zullkiflee N, Taha H, Usman A. Propolis: its role and efficacy in human health and diseases. Molecules 2022;27:6120.
Hossain R, Quispe C, Khan RA, Saikat ASM, Ray P, Ongalbek D, et al. Propolis: an update on its chemistry and pharmacological applications. Chin Med 2022;17.
Granados-Pineda J, Uribe Uribe N, Garcı́a-López P, Ramos Godínez MDP, Rivero Cruz JF, Pérez Rojas JM. Effect of pinocembrin isolated from mexican brown propolis on diabetic nephropathy. Molecules 2018;23:852.
Chavda VP, Chaudhari AZ, Teli D, Balar PC, Vora LK. Propolis and their active constituents for chronic diseases. Biomedicines 2023;11:259.
Seguenı N, Akkal S, Benlabed K, Nieto G. Potential use of propolis in phytocosmetic as phytotherapeutic constituent. Molecules 2022;27:5833.
Ingham JL. Isosativan: an Isoflavan Phytoa lex in from Trifolium hybridum and other Trifolium species. Z Naturforsch 1976;31:331-2.
Sami B, Okoro H, Igoli NP, Igoli J. Isolation of Isosativan from Nigerian Red Propolis. Trop J Nat Prod Res 2020;4:77-9.
Alanazi S, Alenzi ND. Phytochemical profiling and characterization of flavonoid derivatives from propolis sample and investigation of cytotoxic and antiprotozoal activities. Sci Rep 2024;14:21295.
Rivas DA, Lessard SJ, CoffeyV G. mTOR function in skeletal muscle: a focal point for overnutrition and exercise. App Physiol Nut Metab 2009;34:807-16.
Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell 2017;168:960-76.
Perry BD, Caldow MK, Brennan Speranza TC, Sbaraglia M, Jerums G, Garnham A, et al. Muscle atrophy in patients with type 2 diabetes mellitus: roles of inflammatory pathways, physical activity and exercise. PubMed 2016;22:94-109.
Lesmana R, Tandean S, Christoper A, Suwantika AA, Wathoni N, Abdulah R. Propolis as an autophagy modulator in relation to its roles in redox balance and inflammation regulation. Biomed Pharmacoth 2024;175:116745.
Collins SE, Wiegand ME, Werner AN, Brown IN, Mundo MI, Swango DJ, et al. Ras-mediated activation of mTORC2 promotes breast epithelial cell migration and invasion. Mol Biol Cell 2023;34.
Chen X, Li D, Han J, Wang B, Dong Z, Yu L, et al. Reprogramming induced by isoliquiritigenin diminishes melanoma cachexia through mTORC2-AKT-GSK3β signaling. Oncotarget 2017;8:34565-75.
Zou Z, Tao T, Li H, Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosc 2020;10.
Zhou G, Myers RW, Li Y, Chen Y, Shen X, Fenyk Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Inv 2001;108:1167-74.
Sinam IS, Chanda D, Thoudam T, Kim M, Kim B, Kang H, et al. Pyruvate dehydrogenase kinase 4 promotes ubiquitin–proteasome system dependent muscle atrophy. J Cach Sarcop Mus 2022;13:3122-36.
Pinheiro-Dardis CM, Gutierres VO, Assis RP, Peviani SM, Delfino G, Durigan JL, et al. Insulin treatment reverses the increase in atrogin-1 expression in atrophied skeletal muscles of diabetic rats with acute joint inflammation. Ther Clin Risk Man 2018;14:275-86.
Zheng X, Cartee GD. Insulin-induced Effects on the Subcellular Localization of AKT1, AKT2 and AS160 in Rat Skeletal Muscle. Sci Rep 2016;6.
Kim S, Jung J, Chai C, Imm J. Characteristics and glucose uptake promoting effect of chrysin-loaded phytosomes prepared with different phospholipid matrices. Nutrients 2019;11:2549.
Sharma S, Wadhwa K, Choudhary M, Budhwar V. Ethnopharmacological perspectives of glucokinase activators in the treatment of diabetes mellitus. Nat Prod Res 2021;36:2962-76.
Gao J, He X, Ma Y, Zhao X, Hou X, Hao E. Chlorogenic acid targeting of the AKT PH domain activates AKT/GSK3β/FOXO1 signaling and improves glucose metabolism. Nutrients 2018;10:1366.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.